Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Return on Capital Employed (2016 - 2025)

Amicus Therapeutics' Return on Capital Employed history spans 15 years, with the latest figure at 0.05% for Q4 2025.

  • For the quarter ending Q4 2025, Return on Capital Employed rose 1.0% year-over-year to 0.05%, compared with a TTM value of 0.05% through Dec 2025, up 1.0%, and an annual FY2025 reading of 0.05%, up 1.0% over the prior year.
  • Return on Capital Employed for Q4 2025 was 0.05% at Amicus Therapeutics, down from 0.05% in the prior quarter.
  • The five-year high for Return on Capital Employed was 0.07% in Q1 2025, with the low at 0.39% in Q3 2022.
  • Average Return on Capital Employed over 5 years is 0.17%, with a median of 0.22% recorded in 2023.
  • Year-over-year, Return on Capital Employed dropped -13bps in 2022 and then increased 22bps in 2023.
  • Tracing FOLD's Return on Capital Employed over 5 years: stood at 0.26% in 2021, then plummeted by -34bps to 0.35% in 2022, then surged by 64bps to 0.13% in 2023, then skyrocketed by 131bps to 0.04% in 2024, then grew by 25bps to 0.05% in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Return on Capital Employed are 0.05% (Q4 2025), 0.05% (Q3 2025), and 0.03% (Q2 2025).